P8396
Piperacillin sodium salt
penicillin analog
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H26N5NaO7S
化学文摘社编号:
分子量:
539.54
UNSPSC Code:
51282423
NACRES:
NA.85
PubChem Substance ID:
EC Number:
261-868-6
Beilstein/REAXYS Number:
5373920
MDL number:
InChI key
WCMIIGXFCMNQDS-IDYPWDAWSA-M
InChI
1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1
SMILES string
[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O
form
powder
solubility
H2O: soluble 50 mg/mL
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria
mode of action
cell wall synthesis | interferes
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
Chemical structure: β-lactam
Application
Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.
Biochem/physiol Actions
Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.
Packaging
1g,5g,10g
Other Notes
Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
涉药品监管产品
此项目有
João Gonçalves-Pereira et al.
PloS one, 7(11), e49845-e49845 (2012-11-28)
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients
S Christian Cheatham et al.
International journal of antimicrobial agents, 41(1), 52-56 (2012-12-12)
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Fourteen hospitalised patients weighing >120kg received piperacillin/tazobactam 4.5 g every 8 h (q8h) or 6.75 g q8h infused over
Jennifer A Pratt et al.
Pediatric blood & cancer, 61(2), 366-368 (2013-09-17)
Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin-tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with
Zhiping Li et al.
European journal of clinical pharmacology, 69(6), 1223-1233 (2013-01-29)
To develop population pharmacokinetic (PK) models for piperacillin/tazobactam in neonates and infants of less than 2 months of age in order to determine the appropriate dosing regimen and provide a rational basis for the development of preliminary dosing guidelines suitable
N C Schaper et al.
Infection, 41(1), 175-186 (2012-11-28)
The aim was to compare the efficacy and safety of two antibiotic regimens in patients with diabetic foot infections (DFIs). Data of a subset of patients enrolled in the RELIEF trial with DFIs requiring surgery and antibiotics were evaluated retrospectively.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持